Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model

Stem Cells

Volumn 31, Issue 3, 2013, Pages 423-432

  Duarte, Sonia ^a   Momier, David ^b   Baqué, Patrick ^b   Casanova, Vincent ^b   Loubat, Agnès ^b   Samson, Michel ^b   Guigonis, Jean Marie ^b   Staccini, Pascal ^b   Saint Paul, Marie Christine ^c   De Lima, Maria Pedroso ^a,d   Carle, Georges F ^b   Pierrefite Carle, Valérie ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c PASTEUR HOSPITAL   (France)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cancer stem cells; Colon carcinoma; Liver metastases; Vaccination

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE REDUCTASE; HEAT SHOCK PROTEIN 27; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STEM CELL; CELL ISOLATION; CELL LYSATE; CELL SUBPOPULATION; COLON CARCINOMA; CONTROLLED STUDY; LIVER METASTASIS; MALE; MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR VOLUME; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOGENICITY TESTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS; MALE; NEOPLASTIC STEM CELLS; RATS; RETINAL DEHYDROGENASE;

EID: 84874818661     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1292     Document Type: Article

References (63)

1. Steele G, Jr., Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989;210: 127-138.
2. Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009;3: 131-144.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8: 755-768.
4. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445: 106-110.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-115.
6. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med 2007;58: 267-284.
7. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69: 3382-3389.
8. Levi E, Misra S, Du J et al. Combination of aging and dimethylhydrazine treatment causes an increase in cancer-stem cell population of rat colonic crypts. Biochem Biophys Res Commun 2009;385: 430-433.
9. Francescangeli F, Patrizii M, Signore M et al. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells 2012;30: 1819-1830.
10. Sherry MM, Reeves A, Wu JK et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27: 2383-2392.
11. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444: 761-765.
12. Dong Y, Han Q, Zou Y et al. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 2012;370: 89-102.
13. Martin F, Caignard A, Jeannin JF et al. Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer 1983;32: 623-627.
14. Caignard A, Genne P, Olsson NO et al. F11C antigen: A membrane marker able to distinguish two regressive and progressive variants from a rat colon adenocarcinoma. Int J Cancer 1990;46: 633-639.
15. Auerbach R, Morrissey LW, Sidky YA. Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation. Cancer Res 1978;38: 1739-1744.
16. Pierrefite-Carle V, Baque P, Gavelli A et al. Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats. Gut 2002;50: 387-391.
17. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010;22: 132-143.
18. Hatfield P, Merrick AE, West E et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 2008;31: 620-632.
19. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456: 593-598.
20. Deng S, Yang X, Lassus H et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010;5:e10277.
21. Kim MP, Fleming JB, Wang H et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011;6: e20636.
22. Duarte S, Loubat A, Momier D et al. Isolation of head and neck squamous carcinoma cancer stem-like cells in a syngeneic mouse model and analysis of hypoxia effect. Oncol Rep 2012;28: 1057-1062.
23. Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma- derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67: 4010-4015.
24. Joo KM, Kim SY, Jin X et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008;88: 808-815.
25. Wang J, Sakariassen PO, Tsinkalovsky O et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122: 761-768.
26. Ogden AT, Waziri AE, Lochhead RA et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008;62: 505-514; discussion 514-505.
27. Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118: 2111-2120.
28. Chu P, Clanton DJ, Snipas TS et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124: 1312-1321.
29. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163.
30. Prokhorova TA, Harkness LM, Frandsen U et al. Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. Stem Cells Dev 2009;18: 47-54.
31. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8: 329-340.
32. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7: 834-846.
33. Rak J, Milsom C, Yu J. Vascular determinants of cancer stem cell dormancy - Do age and coagulation system play a role?APMIS 2008; 116: 660-676.
34. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
35. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?Nat Rev Drug Discov 2009;8: 579-591.
36. Garrido C, Brunet M, Didelot C et al. Heat shock proteins and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-2601.
37. Wei L, Liu TT, Wang HH et al. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res 2011;13:R101.
38. Tsuruta M, Nishibori H, Hasegawa H et al. Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncol Rep 2008;20: 1165-1172.
39. Sakai A, Otani M, Miyamoto A et al. Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics 2012;75: 806-818.
40. Yao Y, Jia XY, Tian HY et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta 2009;1794: 1433-1440.
41. Wang F, Zhang P, Shi C et al. Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol 2012;29: 1780-1788.
42. Yu Z, Zhi J, Peng X et al. Clinical significance of HSP27 expression in colorectal cancer. Mol Med Report 2010;3: 953-958.
43. Hsu HS, Lin JH, Huang WC et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011;117: 1516-1528.
44. Tammali R, Srivastava SK, Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets 2011;11: 560-571.
45. Peng XC, Gong FM, Wei M et al. Proteomic analysis of cell lines to identify the irinotecan resistance proteins. J Biosci 2010;35: 557-564.
46. Matsunaga T, Yamane Y, Iida K et al. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. Anticancer Drugs 2011;22: 402-408.
47. Lee KW, Ko BC, Jiang Z et al. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 2001;12: 129-132.
48. Bacolod MD, Lin SM, Johnson SP et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008;8: 172-179.
49. Tammali R, Reddy AB, Saxena A et al. Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis 2011;32: 1259-1267.
50. Tammali R, Saxena A, Srivastava SK et al. Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor- 1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating S proteasome-mediated protein degradation in human colon cancer cells. J Biol Chem 2011;286: 24089-24100.
51. Mojtahedi Z, Safaei A, Yousefi Z et al. Immunoproteomics of HER2- positive and HER2-negative breast cancer patients with positive lymph nodes. Omics 2011;15: 409-418.
52. Korneeva I, Bongiovanni AM, Girotra M et al. IgA antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers. Int J Cancer 2000;87: 824-828.
53. Lichtenfels R, Kellner R, Atkins D et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003;1646: 21-31.
54. Shukla S, Govekar RB, Sirdeshmukh R et al. Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex. Proteomics Clin Appl 2007;1: 1592-1604.
55. Hartmann TB, Thiel D, Dummer R et al. SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 2004;150: 252-258.
56. Forgber M, Trefzer U, Sterry W et al. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009;4: e5199.
57. F Lam F, Jankova L, Dent OF et al. Identification of distinctive protein expression patterns in colorectal adenoma. Proteomics Clin Appl 2010;4: 60-70.
58. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 2010;9: 3105-3114.
59. Yokota S, Yamamoto Y, Shimizu K et al. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones 2001;6: 345-350.
60. Srivastava RM, Varalakshmi C, Khar A. The ischemia-responsive protein 94 (Irp94) activates dendritic cells through NK cell receptor protein- 2/NK group 2 member D (NKR-P2/NKG2D) leading to their maturation. J Immunol 2008;180: 1117-1130.
61. Kahle PJ, Waak J, Gasser T. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009;47: 1354-1361.
62. Alvarez-Chaver P, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ et al. Selection of putative colorectal cancer markers by applying PCA on the soluble proteome of tumors: NDK A as a promising candidate. J Proteomics 2011;74: 874-886.
63. Ning N, Pan Q, Zheng F et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012;72: 1853-1864.